Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target on the stock in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ BCLI opened at $0.26 on Friday. The stock has a market capitalization of $18.38 million, a PE ratio of -0.82 and a beta of 0.35. Brainstorm Cell Therapeutics has a one year low of $0.13 and a one year high of $1.08. The business’s fifty day moving average price is $0.33 and its 200-day moving average price is $0.42.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). During the same quarter in the previous year, the company earned ($0.27) EPS. As a group, equities analysts expect that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.